Bilateral Lung Metastases From a Phalangeal Giant Cell Tumor of Bone

2020 ◽  
pp. 109352662096435
Author(s):  
Annie Orr ◽  
Huifei Liu ◽  
Rachel Mariani ◽  
Jennifer H Aldrink ◽  
Bhuvana A Setty ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Residual Disease ◽  
Lung Metastases ◽  
Transcriptome Profiling ◽  
Cell Tumor ◽  
Wide Resection ◽  
Genetic Changes ◽  
Metastatic Lung ◽  
Bilateral Lung

We describe a rare pediatric case of a phalangeal giant cell tumor of bone with extensive bilateral lung metastases following curettage, wide resection, and amputation. Concurrent peripheral blood eosinophilia and pleural effusion with marked eosinophilia (47%) were present. To discover genetic changes driving tumor metastasis, genomic and transcriptome profiling of the metastatic lung mass as well as germline analysis were performed. Whole exome sequencing detected a histone H3F3A p.G35V missense mutation in tumor cells. RNA sequencing revealed overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL). The patient is alive with no residual disease and uncompromised respiratory function 29 months after amputation of primary tumor and 19 months after surgical resection of his metastatic lung disease.

scholarly journals Multiple Pulmonary Metastases of Giant Cell Tumor of Bone with expression of VEGFR-2 Successfully Treated by Denosumab and Apatinib: A Rare Case Report

2021 ◽  
Author(s):  
taojun gong ◽  
Yi Luo ◽  
Yitian Wang ◽  
Chuanxi Zheng ◽  
Jianguo Fang ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Case Report ◽  
Local Recurrence ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Pulmonary Metastases ◽  
Cell Tumor ◽  
Wide Resection ◽  
High Tendency ◽  
Bony Destruction

Abstract Background: Giant cell tumor of bone (GCTB) is a rare benign but locally aggressive bone tumor. It has a high tendency for local recurrence, which may increase the occurrence of lung metastasis. Currently, the treatment of pulmonary metastases of GCTB is controversial. Denosumab is the preferred regimen for unresectable metastatic lesions, but there are no alternative treatment options when denosumab is resistant. So far, no case reports of metastatic GCTB treated with denosumab and apatinib have been published. Case presentation: This is a case report of a 26-year-old female who experienced right knee pain for over 6 months. Radiography and computed tomography revealed osteolytic bony destruction in the proximal right tibia. Using histological, radiological, and clinical techniques, a diagnosis of GCTB was achieved. Meanwhile, the immunohistochemical stain-identified the tumor cells were positive for vascular endothelial growth factor receptor 2 (VEGFR-2). After intralesional curettage of the primary tumor and wide resection of local recurrence surgeries, she developed recurrent hemoptysis. Chest computed tomography (CT) images showed multiple pulmonary nodules. She was administrated denosumab therapy but disease progression was confirmed after four months of treatment. She then received denosumab and apatinib therapy for 24 months, after a partial response was achieved.Conclusions: We depict a case of multiple pulmonary metastases of GCTB successfully controlled by denosumab and apatinib therapy. VEGFR-2 may be an effective therapeutic target for GCTB with pulmonary metastasis when denosumab is ineffective.

scholarly journals Multicentric Giant Cell Tumor of the Fourth and Fifth Metacarpals with Lung Metastases

Hand ◽  
2013 ◽  
Vol 9 (3) ◽  
pp. 389-392 ◽  
Author(s):  
Nash H. Naam ◽  
Steven L. Jones ◽  
Justin Floyd ◽  
Esat I. Memisoglu
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Lung Metastases ◽  
Cell Tumor

scholarly journals Characteristics Giant Cell Tumor of The Bone Cases at Dr. Mohammad Hoesin General Hospital Period 1 January 2017 - 31 Augsut 2020

2021 ◽  
Vol 5 (3) ◽  
pp. 546-552
Author(s):  
Primadika Rubiansyah ◽  
Randy Rakhmat Septiandani
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
General Hospital ◽  
Lung Metastases ◽  
Cell Tumor ◽  
Primary Bone Tumor ◽  
Grade Ii ◽  
Male Patients ◽  
Group 2 ◽  
Short Time

Introduction : Giant Cell Tumor (GCT) is a benign bone tumors with potentially aggressive and capacity to metastasize. This tumor could destroy the bone and joint component. As a primary bone tumor that appears at productive age , GCT can cause morbidity for patients. Methods : This research is a retrospective descriptive study with data obtained from the medical records of patients who went to Mohammad Hoesin general hospital for the period January 1, 2017- August 31, 2019. Data processing was carried out using SPSS 16.0. From the research results, 27 GCT patient data that met the inclusion criteria were obtained. Results : There were 23 (85.1%) patients in the 20-44 years age group, 2 (7.4%) people <20 years, 2 (7.4%) people> 44 years. There were 13 (48%) male patients and 14 (52%) female patients. The most common tumor locations were in the proximal tibia as many as 6 (22%) people, Distal Femur as many as 6 (22%) people, Distal Radius as many as 5 (18.5%) people, Distal Ulna as many as 3 (11.1%) people, Proximal Femur as many as 1 (3.7 %) people, Calcaneus as much as 1 (3.7%) people, Metacarpal as many as 1 (3.7%) people. Based on grading Campanacci, 16 (59.25%) people had GCT with Campanacci Grade III, Grade II with 8 (29.6%) people, and 1 (3.7%) grade I. Only 2 (7.4%) people had recurrences. No patients were found to have lung metastases (0%). There were 1 (3.7%) patients with pathological fracture on GCT. Management carried out was 24 people undergoing resection and reconstruction 24 (88.5%) and 3 (11.5%) people with curettage and bone cement. Conclusion : This study of GCTB at Mohammad Hoesin general hospital bring out that patient’s characteristics are similar with other country and theory. Mostly patient got GCTB at age second until fouth decade of life, slightly more in female, mostly tumor detected around the knee. Mostly patient detected with Campanacci graded III and needed resection and reconstruction surgery. No reported lung metastases in GCTB patient but this record need further follow up due to short time between surgery and study

scholarly journals Identifying differentially expressed genes and key pathways in giant cell tumor of bone by transcriptome profiling

2018 ◽  
Vol 29 ◽  
pp. vii77
Author(s):  
Joseph C. Tsui ◽  
Carol P. Lau ◽  
Leon M. Shi ◽  
Stephen K. Tsui ◽  
Shekhar M. Kumta
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Differentially Expressed Genes ◽  
Transcriptome Profiling ◽  
Cell Tumor ◽  
Differentially Expressed ◽  
Key Pathways

Metastasectomy Versus Non-Metastasectomy for Giant Cell Tumor of Bone Lung Metastases

Orthopedics ◽  
2021 ◽  
pp. 1-6
Author(s):  
Shinji Tsukamoto ◽  
Andreas F. Mavrogenis ◽  
Yuu Tanaka ◽  
Akira Kido ◽  
Kanya Honoki ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Lung Metastases ◽  
Cell Tumor

EXCISION OF GIANT CELL TUMOR FOLLOWED BY RECONSTRUCTION OF DISTAL RADIUS USING FREE VASCULARIZED FIBULAR GRAFT

2019 ◽  
Vol 1 (4) ◽  
Author(s):  
Prisca Oriana Sutanto ◽  
Agus Roy Rusli Hamid ◽  
Adinda Putra Pradhana
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Distal Radius ◽  
Tumor Resection ◽  
Cell Tumor ◽  
Wide Resection ◽  
Fibular Graft ◽  
Maximum Function ◽  
Vascularized Fibular Graft ◽  
Free Vascularized Fibular Graft

Giant cell tumor (GCT) of the distal radius is a rare and unpredictable lesion. The aim of treatment is complete removal of the tumor and preservation of the maximum function of the extremity. Lower rates of local recurrence have been noted after wide resection of the diseased bone. Its standard treatment has ranged from surgical curettage to wide resection. One method for closing the defect is using the head of the fibula as a substitute for the distal radius. The healing of vascularized fibular graft is very quick and without bone resorption. Thus, in the procedure for reconstruction and limb salvage after bone tumor resection of the distal radius, the free vascularized fibular graft with the fibular head is an ideal substitute. This case report will show a patient with GCT that successfully treated by an excision of GCT followed by reconstruction of distal radius using free vascularized fibular graft.

scholarly journals Giant Cell Tumor of the Metacarpal: Case Report

Hand ◽  
2017 ◽  
Vol 12 (5) ◽  
pp. NP113-NP117 ◽  
Author(s):  
Laura W. Lewallen ◽  
Eric R. Wagner ◽  
Steven L. Moran
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Treatment Options ◽  
Cell Tumor ◽  
Lytic Lesion ◽  
Wide Resection ◽  
Intralesional Curettage ◽  
Female Predominance ◽  
Long Term Follow Up ◽  
Small Bones

Background: Giant cell tumor (GCT) of bone is a benign, though locally aggressive tumor, classically described as an eccentric lytic lesion, often with cortical expansion and destruction. It typically involves the metaphysis or epiphysis of long bones in skeletally mature patients, with a slight female predominance. The incidence in the small bones of the hand has been reported to be 2% to 5%. Methods: Treatment options have evolved in recent years, and currently include intralesional curettage with or without adjuvant therapy, wide resection, and occasionally amputation. Results: In this report, we present a long-term follow-up (10 years) of a patient with GCT involving a metacarpal, who was initially reconstructed with a metacarpal head allograft, which was eventually revised to a metacarpophalangeal (MCP) total joint arthroplasty. Conclusions: To our knowledge, this is the only report of pyrocarbon being used for tumor reconstruction and the only report of late MCP allograft salvage.

Sign in / Sign up

Export Citation Format

Share Document